Patients with acute myeloid leukemia (AML) in remission for over 3 years experience survival rates comparable with a matched cohort from the general population.

Approximately 60% to 70% of patients aged 18 to 65 years will achieve a complete remission, but just 30.5% of these patients ...

The FDA has granted orphan drug designation to ligufalimab, a CD47 monoclonal antibody, for treatment of acute myeloid ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company ...

Researchers executed a phase 1b study to determine the safety and efficacy of venetoclax combined with a 7+3 chemotherapy regimen in treating acute myeloid leukemia.

The FDA granted orphan drug designation to ligufalimab for AML, reflecting its potential as an immune-based therapy that may ...

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN®) ...

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. Researchers at Baylor College of Medicine, University of Veterinary ...

Child influencer Zuza Beine has died at age 14 following an 11-year cancer battle. Her family shared the news with the teenagers 1.9m Instagram followers. "It is with broken hearts that we share that ...